ApoImmune

ApoImmune is a pre-clinical stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company utilizes its proprietary Apo-Tuner platform to design hexameric TNF receptor superfamily (TNFRSF) agonists that mimic natural ligand-receptor interactions more effectively than traditional bivalent antibodies. Their lead programs target key costimulatory pathways including OX40, 4-1BB, and GITR to enhance T-cell activation and anti-tumor immunity. By engineering stable, high-potency fusion proteins, ApoImmune aims to overcome the efficacy and safety limitations associated with first-generation TNFRSF-targeting agents.